PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

106 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-02-26

Study Completion Date

2024-02-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Resectable esophageal or junctional cancer requires medical treatment by radiotherapy and chemotherapy followed by surgery. Currently, one of the most commonly used chemotherapy treatment is the FOLFOX. It is a combination of three drugs administered intravenously: fluorouracil, oxaliplatin and folinic acid. This is the standard treatment.

Another protocol of chemotherapy is widely used by certain European and American teams, due to promising results : a combination of two drugs administered intravenously: Paclitaxel and Carboplatin (CarboP-pacliT). At present, no clinical study has shown the superiority of one treatment over the other.

The objective of this Phase II study is to clarify clinical practice by comparing these two chemotherapy treatments.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

FOLFOX-Cetuximab-radiotherapy for the Treatment of Esophageal Cancer

NCT00578201

Esophageal Cancer Stage III

COMPLETED PHASE2

Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer

NCT00861094

Esophageal Cancer

COMPLETED PHASE2/PHASE3

Benefit of Chemotherapy Over Best Supportive Care in Metastatic and Squamous Cell-type Esophageal Cancer.

NCT01248299

Squamous Cell Carcinoma of Esophagus

TERMINATED PHASE2

Radiochemotherapy With and Without Dose Escalation in Patients Presenting Locally Advanced or Inoperable Carcinoma of the Oesophagus

NCT01348217

Esophageal Cancer

COMPLETED PHASE2/PHASE3

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer

NCT00021320

Esophageal Cancer

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

There is no standard preoperative (neoadjuvant) chemoradiation (NCRT) regimen for resectable esophageal cancer, because most if all trials failed to show any survival advantage favoring pCRT when compared to surgery only. This failure had been related to the lack of power of some trials, as well as the ability of chemoradiation to potentiate post-operative morbidity (including mortality), and therefore hampering the accrual of its own survival benefit. Hopefully, meta-analyses showed that NCRT increases survival when compared to surgery only. However, in the clinical practice, this does not make easier the choice of the best NCRT treatment. It appeared that the radiation regimen that were used in each randomized trials were heterogeneous with respect with dose, fraction, length of treatment, fields, dosimetry planning, and quality control. This applies also to chemotherapy with respect with the kind of cytotoxics that were used (including number of drugs), as well as dosage, and the number of cycles, although most of the time cytotoxics were fluorouracil and cisplatin.

Dutch colleagues recently showed that NCRT with weekly carboplatin and paclitaxel increase survival, without increasing postoperative mortality. Of note, most tumors in this trial arose from the lower third of the esophagus and esogastric junction and these habitually correlate with less postoperative morbidity compared to upper third tumors. Moreover, the lung volume spared from radiation was greater in junctional tumors than in upper third cancers - a critical point in the development of radiation-induced pneumonitis and subsequent postoperative mortality. It is difficult to understand how this taxane-based chemotherapy is active, as it did not make better that fluorouracil-based regimen in non-operable patients, and as NCRT with taxanes makes radiation-induced pneumonitis more likely. The favorable impact of this NCRT may lie on its radiation regimen. A moderate total dose of radiation, smaller radial margins than in other trials and modern dosimetry with 3D-planning all improve the safety of treatment and of subsequent surgery. Finally, the favorable impact of the Dutch NCRT regimen may lies on the fact that it does not include cisplatin, a compound which has been found related to the occurrence of more sudden deaths than a non cisplatin-based regimen such as the FOLFOX combination (fluorouracil, oxaliplatin, folinic acid) in the setting of definitive chemoradiotherapy.

Our aim is to evaluate the short-term benefit (complete resection rate) and safety (severe postoperative rate) of 2 preoperative regimen, (carboplatin-paclitaxel or fluorouracil-oxaliplatin-folinic acid), combined to the Dutch radiation backbone, in operable esophageal and junctional (Siewert I-II) cancer. The present trial offers the unique opportunity to compare two therapeutic strategies that have already been shown to be efficient in large randomized controlled trials offering level-1 evidence.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Esophageal Neoplasms Gastro-esophageal Junction Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

FOLFOX

* Fluorouracil 400 mg/m², IV bolus dose on day 1, followed by continuous IV infusion of fluorouracil 1600 mg/m² over 2 days
* Oxaliplatin 85 mg/m², 2-hr IV infusion on day 1
* Folinic acid 200 mg/m² 2-hr IV infusion on day 1
* 3 cycles, q14

Group Type ACTIVE_COMPARATOR

FOLFOX

Intervention Type DRUG

radiochemotherapy before surgery

CarboP-pacliT

* Carboplatin (carboP) AUC=2, given by intravenous infusion
* Paclitaxel (pacliT) 50 mg/m², given by intravenous infusion
* on days 1, 8, 15, 22 and 29

Group Type EXPERIMENTAL

CarboP-pacliT

Intervention Type DRUG

radiochemotherapy before surgery

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FOLFOX

radiochemotherapy before surgery

Intervention Type DRUG

CarboP-pacliT

radiochemotherapy before surgery

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Fluorouracil Oxaliplatin Folinic acid Elvorine Carboplatine paclitaxel

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Resectable and operable esophageal cancer located under the carena (beyond 25 cm from the incisors) or junctional cancer (Siewert I or II)
* Invasive adenocarcinoma or squamous cell type (to stick to the population included in the CROSS trial)
* Patient who present with:

* stage IIA (T3N0M0)
* stage IIB (T1 N1 M0 or T2 N1 M0),
* stage III (T3 N1 M0 or T4 N0 N1 M0) tumors
* ECOG performance status 0, 1 or 2
* Patient eligible for preoperative chemoradiation with either fluorouracil- oxaliplatin-folinic acid, or Paclitaxel-carboplatin
* Age ≥ 18
* Peripheral neuropathy ≤ NCI-CTC grade 1
* Adequate bone marrow reserve, normal renal and liver functions:

* Neutrophil count ≥ 1500/mm3
* Platelet count ≥ 100 000/mm3
* Hemoglobin ≥ 10 g/dl (after transfusion, if necessary)
* Creatinin \< 15mg/L
* Clearance of creatinin (Cockcroft formulae) ≥ 60 ml/mn
* Prothrombin time ≥ 60%
* ASAT-ALAT ≤2.5 x ULN
* Total bilirubin \< 1.5 x ULN
* Albumin greater the lower limit of normal
* Start of treatment within 28 days after randomization
* Negative pregnancy test (serum beta-HCG) performed within 1 week prior to start of study treatment in females with reproductive potential
* Patient covered by government health insurance
* Patient who provide a signed written informed consent form

Exclusion Criteria

* Patient who present with stage I or stage IIA (including T2 N0 M0) or stage IV
* Patient who present with common contraindications for surgery related to patient status
* Patient who present with common contraindications for surgery related to disease extension
* Patient who present with common contraindication to radiochemotherapy with either fluorouracile-cisplatin or with paclitaxel-carboplatin

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No